Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions
AssigneeNew Frontier Labs, LLC
InventorsRobert T. Streeper, Elzbieta Izbicka
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising a C1-C4 alkyl ester azelate, such as diethyl azelate (DEA), dimethyl azelate (DMA), di-isopropyl azelate (DiPA), di-isobutyl azelate (DiBuA), and di-2-pentyl azelate (D2PA), and methods of, inter alia, improving abnormal lipid levels and treating or preventing dyslipidemias and/or diseases of conditions associated therewith comprising administering to a subject such pharmaceutical compositions, are provided.
Claims5
A pharmaceutical composition formulated for buccal delivery and comprises diethyl azelate in an amount of 0.5 mg/kg, and a buccally acceptable carrier, wherein the composition provides an improvement when compared to a composition containing the same amount of diethyl azelate but formulated for gastric delivery, the improvement in one or more selected from the group consisting of:
- lowering low-density lipoprotein (LDL) levels;
- lowering a ratio of cholesterol to high density lipoprotein (HDL), lowering a LDL/HDL ratio;
- and reducing cholesterol.
Dependencies are inferred from the claim text.